| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Kalvista Pharmaceuticals, Inc. (KALV) has 12 insiders with recent SEC Form 4 filings, including 0 buys and 29 sells. KALV is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 462.6K | $12.49M | - | |
| Other | 223.5K | $6.03M | - | |
| Other | 142.5K | $3.85M | - | |
| Other | 100.0K | $2.70M | - | |
| Other | 51.4K | $1.39M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Mar 18, 2019 | Venrock Healthcare Capital Partners Ii, L.P. | 10% Owner | Sell | 500,000 | $28.75 | $14,375,000.00 | -24.5% | |
| Mar 14, 2019 | Crockett Thomas Andrew72 | CEO | Sell | 3,000 | $30.16 | $90,483.90 | -1.1% | |
| Mar 5, 2019 | Svlsf Iv, LLC | 10% Owner | Sell | 75,710 | $22.96 | $1,738,475.96 | -1.6% | |
| Feb 21, 2019 | Svlsf Iv, LLC | 10% Owner | Sell | 214,198 | $20.55 | $4,401,353.41 | -2.8% | |
| Jan 25, 2019 | Yea Christopher53 | Chief Development Officer | Sale+OE | 5,453 | $17.06 | $93,015.09 | -6.2% | |
| Jan 23, 2019 | Yea Christopher53 | Chief Development Officer | Sale+OE | 1,902 | $17.01 | $32,343.93 | -1.1% | |
| Jan 16, 2019 | Feener Edward P.72 | Chief Scientific Officer | Sell | 4,000 | $19.55 | $78,209.88 | -1.9% | |
| Jan 14, 2019 | Crockett Thomas Andrew72 | CEO | Sell | 10,000 | $19.33 | $193,328.29 | -1.8% | |
| Jan 7, 2019 | Svlsf Iv, LLC | 10% Owner | Sell | 4,299 | $20.25 | $87,072.89 | - | |
| Jan 2, 2019 | Svlsf Iv, LLC | 10% Owner | Sell | 29,352 | $20.01 | $587,242.49 | -0.4% |